TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06569238

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional bacterial culture
Description: Participants will have DFU ulcer tissue collected and sent to the laboratory (per usual care practices) that includes the use of conventional bacterial culture analysis (i.e., plates).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Conventional bacterial culture
Description: Participants will have DFU ulcer tissue collected and sent to the laboratory (per usual care practices) that includes the use of conventional bacterial culture analysis (i.e., plates).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic group using mNGS technology
Description: Participants will have DFU ulcer tissue collected and have metagenomics sequencing performed. The name of the devices listed for this study are the Illumina MiSeq System with MiSeq Reagent Kit V2 from Illumina and the MinION sequencer (Oxford Nanopore Technologies).
Study: NCT06571253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Exercise Intervention
Description: Participants in this intervention arm used the Fiziu Digital Physiotherapy Platform. This digital platform provided a structured 6-week corrective exercise program through visual and auditory-guided videos. The intervention included interactive features such as reminders and progress tracking to enhance adherence and engagement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paper-Based Exercise Intervention
Description: Participants in this intervention arm followed a traditional paper-based exercise program. This included printed exercise instructions and illustrations for a 6-week period. The program was designed to mimic standard physical therapy exercises without digital support.
Study: NCT06222866

Intervention type: DIAGNOSTIC_TEST
Intervention: Anticoagulation monitoring
Description: Evaluation of different monitoring modalities to find the most appropriate anticoagulation monitoring tool for UFH therapy
Study: NCT05703945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive training program
Description: The intervention consists of progressive training program : toe plantar flexion isometric at 30° of dorsal flexion of the metatarsophalangeal joint (0° is considered the anatomical position). The training will be performed in the same customized device used for the measurement. Each session consists of four sets at 80% of the maximal voluntary contraction performed until task failure. Between the sets, 2 minutes of rest will be allowed. Maximal voluntary contraction estimate will be updated every session of training, testing it before the start. The test is considered part of the training intervention. The total impulse performed during the single session will be recorded. Participants will train twice a week for 8 weeks. Training will be performed with both the feet.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The control group will not perform the progressive training program after visit 2 and will continue all of their daily activities during the 8-week intervention period.
Study: NCT04101955

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Incisionless Threaded Carpal Tunnel
Description: ultra-minimally invasive thread carpal tunnel release

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Incisionless Threaded Carpal Tunnel
Description: ultra-minimally invasive thread carpal tunnel release

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Mini-Open Carpal Tunnel
Description: open surgical carpal tunnel release

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Mini-Open Carpal Tunnel
Description: open surgical carpal tunnel release
Study: NCT05985161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension .
Study: NCT06581016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu aScope Gastro
Description: CE-marked single-use gastroscopes from Ambu are used in the single-use group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu aScope Gastro Large
Description: CE-marked single-use gastroscopes from Ambu are used in the single-use group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic gastroscopes, Olympus
Description: Reusable gastroscopes from Olympus are used in the reusable group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic gastroscopes, Olympus
Description: Reusable gastroscopes from Olympus are used in the reusable group.
Study: NCT04534244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VBox Hybrid
Description: Medical device intended to treat permanent venous insufficiency of saphenous veins and tributary veins in patients with superficial venous reflux
Study: NCT05975671

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Multifaceted de-implementation strategy to reduce vancomycin overuse
Description: * Clinical guidelines and group-level feedback on vancomycin use will be provided to clinicians/sepsis stakeholders at each site.~* The semi-structured interviews will be performed by a trained member of the research team, under the supervision of a medical sociologist who is one of the co-investigators. A semi-structured interview guide will be used during the interviews. Interviews will be recorded and transcribed, then uploaded to a qualitative analysis software for management and coding. Names will not be recorded, and pseudonyms will be used in notes, communications about the study, and any presentations. Verbal consent will be obtained before conducting and recording the interviews.~* The surveys will be performed using REDCap survey software, and participation will be voluntary. No identifiers will be collected.
Study: NCT05899634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Defaults
Description: Participants will receive healthy recipes (3 main meal + 1 snack/breakfast/lunch recipe per week of the two-week intervention). In addition, in this group, participants' online grocery shopping carts will be pre-filled with ingredients corresponding to the provided recipes. They will be told that their cart has been filled with items that can be used to make recipes from the provided recipe cards, and that they can modify it as they like.
Study: NCT05641545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVAC
Description: IVAC is a personalized peptide vaccine
Study: NCT06099184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP-1901
Description: Intravitreal Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP-1901
Description: Intravitreal Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2Mg/0.05Ml Inj,Oph
Description: Intravitreal Injection
Study: NCT05757505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial Stent (Tonbridge)
Description: Endovascular treatment with Intracranial Stent (Tonbridge).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wingspan Stent System (Stryker Neurovascular)
Description: Endovascular treatment with Wingspan Stent System (Stryker Neurovascular).
Study: NCT05263934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depemokimab
Description: Depemokimab will be administered

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab
Description: Mepolizumab will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching mepolizumab
Description: Placebo matching to mepolizumab will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching depemokimab
Description: Placebo matching to depemokimab will be administered.
Study: NCT05380466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantum Touch
Description: Quantum-Touch is one of the therapeutic touch techniques, a biofield therapy that uses life force energy to facilitate healing
Study: NCT04733768

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007
Description: 18f-PSMA-1007 PET/CT scan
Study: NCT06356337

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light goggles
Description: Blue light goggles designed to promote circadian entrainment will be worn for 1 hour each morning for two weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light goggles
Description: Blue light goggles designed to promote circadian entrainment will be worn for 1 hour each morning for two weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orange glasses
Description: Orange glasses that do not provide entrainment will be worn for 1 hour each morning to block morning light for two weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orange glasses
Description: Orange glasses that do not provide entrainment will be worn for 1 hour each morning to block morning light for two weeks.
Study: NCT06582225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered exposure and response prevention (I-ERP)
Description: The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, emotions, healthy habits, the difference between repetitive behaviours in autism and OCD, how compulsions maintain the obsessions, and the rationale for ERP. The main focus of the treatment is ERP tasks based on the young person's individual goals. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of ERP. The final module includes a summary of the treatment and a relapse prevention plan.~The version for parents consists of the same content as the child treatment, but with elaborated psychoeducation, and additional focus on strategies on how to assist their child in the different exposure tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered stress management (I-SM)
Description: The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, healthy habits, and how stress is a contributor to OCD symptoms. The rationale is that targeting and reducing stress will have a beneficial impact on anxiety, obsessions, and compulsions. The main goal of the treatment is to learn how to reduce stress, mainly by using relaxation techniques such as deep breathing, progressive muscle relaxation, and imagery (cognitive) relaxation. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of relaxation tasks.~The version for parents contains psychoeducation, as well as strategies on how to assist their child in the different relaxation tasks.
Study: NCT06527066

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Geranium (Pelargonium graveolens) essential oil (EO) diluted to 1% in All.me Beauty® Gel Sérum Biocompatível
Description: Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gel Sérum Biocompatível All.me Beauty®
Description: Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks.
Study: NCT04850105

Intervention type: OTHER
Intervention: Data Collection
Description: Data on each patient will be collected at study enrollment and at each follow-up visit.~No mandatory visits, tests, or assessments are required for this study. All visits will be scheduled and conducted according to the clinical site's normal clinical practice.

Intervention type: OTHER
Intervention: Data Collection
Description: Data on each patient will be collected at study enrollment and at each follow-up visit.~No mandatory visits, tests, or assessments are required for this study. All visits will be scheduled and conducted according to the clinical site's normal clinical practice.
Study: NCT05355701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799933
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799933
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799933
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799933
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Injection for intravenous use
Study: NCT04993885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: The subjects will receive avatrombopag treatment with an initial dose of 40mg once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until week 12 after treatment. The dose adjustment range is 20 mg per week to 40 mg per day to maintain the platelet level between 30×10\^9/L and 200×10\^9/L. If the platelet count does not reach to 30×10\^9/L after taking avatrombopag 40mg once a day for 4 consecutive weeks, the treatment will be stopped.
Study: NCT06474286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride 1 MG
Description: The study drug Tab. Prucalopride 1 mg (30 tablets) will be dispensed to the participant. The drug will be procured at the local site manufactured in India only.They will be explained to take one tablet of 1 mg Prucalopride per oral in the morning. The participants will continue their antipsychotic regimen as per orders of their consultant and will continue to purchase their psychiatric medications as earlier. At the end of week 1, participants will be assessed for side effects via telephonic conversation.
Study: NCT05139992

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Vaccination against SARS-CoV-2
Study: NCT05017363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENGAGE
Description: Goal-setting approach and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS), which is established goal setting tools for children aged 5-9. Administration of the Canadian Occupational Performance Measure (COPM), the most widely used goal-setting tool in paediatric rehabilitation that has been used with children as young as seven years. Introducing simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
Study: NCT05287113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab 500mg will be administered intravenously every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab 500mg will be administered intravenously every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab 500mg will be administered intravenously every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 350mg will be administered intravenously every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 350mg will be administered intravenously every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN02390 400 mg will be administered intravenously every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered intravenously.
Study: NCT03732417

Intervention type: OTHER
Intervention: Secondary prevention of cardiovascular risk factors
Description: Intervention group (n=35) Control group (n=35)
Study: NCT06610136

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine plus Resistance training
Description: Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine plus Resistance training
Description: Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Resistance training
Description: Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Resistance training
Description: Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
Study: NCT06368050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: practice structure intervention
Description: practice structure intervention
Study: NCT05173194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Eight-week program of a remotely supervised resistance exercise. Frequency: three times per week. Duration: 60 minutes per session. Training program: warm-up and joint mobility; strength exercises for different muscle groups; and cool down (stretching and breathing exercises).
Study: NCT05586581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV2A PET
Description: SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV2A PET
Description: SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSPO PET
Description: TSPO PET scan with radiotracer \[11C\]PBR28 for imaging of neuroimmune status
Study: NCT06320457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief case management intervention
Description: The brief case management intervention aims to support patients during the difficult phase of involuntary hospitalisation and reduce the impact of this short-term event on their long-term recovery process. The intervention starts during the hospital stay, at the latest one week after admission, and lasts for a maximum of one month after discharge. The intervention consists of five sessions, the order of which may vary according to the specific needs of the patient:~1. Personal account of involuntary hospitalisation and its consequences~2. Presentation of the personal recovery model and the tools to promote it and prevent coercion~3. Introduction to the personal recovery plan~4. Network meeting and discussion on dignity of risk~5. Personal recovery plan
Study: NCT05741424

Intervention type: DIAGNOSTIC_TEST
Intervention: Innovative diagnostic technologies
Description: Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions

Intervention type: DIAGNOSTIC_TEST
Intervention: Reference diagnostic technique
Description: Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
Study: NCT06184529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The virtual reality simulation includes a one time viewing of a brief video tutorial and then trying out a one time virtual reality simulation with a child avatar that takes 10-20 minutes to complete in-person.
Study: NCT05018000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial navigation
Description: The CAFÉ intervention is a financial navigation intervention. During the Intervention, a CAFÉ financial navigator will provide information support and resources to people with cancer after diagnosis. CAFÉ intervention components include: (1) proactive assessment of patient financial questions and concerns (e.g., acute financial need or inability to pay for household expenses; deciding between care options depending on cost; uncertainty around planning for out of pocket costs and/or when patients will need to pay), (2) proactive, personalized support and referrals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial navigation
Description: The CAFÉ intervention is a financial navigation intervention. During the Intervention, a CAFÉ financial navigator will provide information support and resources to people with cancer after diagnosis. CAFÉ intervention components include: (1) proactive assessment of patient financial questions and concerns (e.g., acute financial need or inability to pay for household expenses; deciding between care options depending on cost; uncertainty around planning for out of pocket costs and/or when patients will need to pay), (2) proactive, personalized support and referrals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: The financial resource sheet lists and describes existing internal and community resources available to KP members
Study: NCT05062174

Intervention type: DRUG
Intervention: Mifepristone 200 MG
Description: Orally, one time dosage of 200 mg

Intervention type: PROCEDURE
Intervention: Prophylactic mastectomy
Description: Planned prophylactic mastectomy (having one or both breasts removed).